Primavera

PRIMAVERA ONLINE SCHOOL HAS 2023 COMMENCEMENT CEREMONY WITH ONE OF THE LARGEST GRADUATING CLASSES IN THE STATE

Retrieved on: 
Monday, July 17, 2023
Online, Workforce, Xavier University, Ed Belfour High Performance Award, Primavera, Life, GPA Footballer of the Year, Arizona Financial Theatre, NAU, Primavera Online High School, Student, ASU, GCU, Nursing

CHANDLER, Ariz., July 17, 2023 /PRNewswire/ -- Primavera Online School, a public charter school that educates students across Arizona, celebrated its graduating Class of 2023 on July 6 at the Arizona Financial Theatre with nearly 1400 graduates.

Key Points: 
  • CHANDLER, Ariz., July 17, 2023 /PRNewswire/ -- Primavera Online School, a public charter school that educates students across Arizona, celebrated its graduating Class of 2023 on July 6 at the Arizona Financial Theatre with nearly 1400 graduates.
  • "We are so proud of our 2023 graduates," said Jessica Pagoulatos, Executive Director of Academics at Primavera Online.
  • There were also 159 graduating seniors who earned Primavera's exclusive Performance Award, a monetary award funded by StrongMind that goes toward college, trade school, certifications and the military.
  • Families who are interested in switching their children to Primavera Online School can now enroll them in grades K-12 at PrimaveraOnline.com.

ARIZONA PBS AND PRIMAVERA ONLINE SCHOOL ANNOUNCE WINNERS OF STATEWIDE K-5 WRITING CONTEST

Retrieved on: 
Thursday, June 15, 2023
Online, Mass communication, Primavera, 3D, Journalism, KAET, ThinkPad, Walter Cronkite School of Journalism and Mass Communication, Primavera Online High School, K-12, Student, Reading, Lenovo, POGO, Tutoring

CHANDLER, Ariz., June 15, 2023 /PRNewswire/ -- The winners of this year's Arizona PBS Writing Contest, sponsored by Primavera Online School, a tuition-free, public charter school for grades K-12, have been announced.

Key Points: 
  • CHANDLER, Ariz., June 15, 2023 /PRNewswire/ -- The winners of this year's Arizona PBS Writing Contest, sponsored by Primavera Online School, a tuition-free, public charter school for grades K-12, have been announced.
  • The children's writing contest, which was open to all elementary school students across Arizona, asked students to imagine what the future of school might be like by writing and/or illustrating a fiction or nonfiction story.
  • "We are so pleased to partner with Arizona PBS and sponsor this year's writing contest that asked students to imagine what the future of school might look like," said Jessica Pagoulatos, Executive Director at Primavera Online.
  • "As one of the first in Arizona to enter the online space, we at Primavera like to think of our school as being at the forefront of what school will be like in the future."

Pixium Vision announces its consolidated financial statements for the financial year 2022 and the consolidated cash balance for March 31, 2023

Retrieved on: 
Friday, April 21, 2023
Area studies, Health, Private law, AMD, CIR, Clinical trial, Research, ESGO, Argus retinal prosthesis, Vision, Research and development, Development, Patient, Investment, Primavera, Next Generation, FDA, Cryptocurrency, Pharmaceutical industry

Pixium Vision ended 2022 with a net cash position of €7.7 million, compared to €14.5 million at the end of 2021.

Key Points: 
  • Pixium Vision ended 2022 with a net cash position of €7.7 million, compared to €14.5 million at the end of 2021.
  • On January 12, 2023, Pixium Vision announced publication of peer-reviewed articles demonstrating the potential of the Next Generation PRIMA implant.
  • On February 13, 2023, Pixium Vision announced the termination of the convertible note financing agreement with US-based healthcare investor ESGO.
  • On March 17, 2023, Pixium Vision announced the reduction of share capital, due to losses, by reduction of nominal value: number of shares unchanged.

Pixium Vision announces completion of implantations in the European pivotal trial PRIMAvera and confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024

Retrieved on: 
Thursday, December 15, 2022
Diamond, Primavera, Physician, AMF, Geographic atrophy, Mnemos EP, Vance DeGeneres, AMD, Rehabilitation, LogMAR chart, IMO, CET, Safety, PRIMA, EN, Moorfields Eye Hospital, Vision Institute, Visual acuity, Stanford University, Risk, Peripheral vision, University of Pittsburgh School of Medicine, Research, Wilfrid Sellars, University, Retinal degeneration, Patient, Prima, UPMC, Medical device, Medical imaging, Pharmaceutical industry

A total of 38 patients have been implanted with the Prima System in the PRIMAvera study (NCT04676854), an open-label, baseline-controlled, non-randomized, multi-center, prospective, single-arm pivotal trial.

Key Points: 
  • A total of 38 patients have been implanted with the Prima System in the PRIMAvera study (NCT04676854), an open-label, baseline-controlled, non-randomized, multi-center, prospective, single-arm pivotal trial.
  • The study is being conducted in leading clinical centers in France, Germany, the UK, the Netherlands, and Italy.
  • A read-out of the PRIMAvera study's primary endpoints is expected around the end of 2023.
  • Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.

Pixium Vision announces the publication of peer-reviewed clinical data of the Prima System in Dry AMD in the Journal of Neural Engineering

Retrieved on: 
Tuesday, October 11, 2022
Diamond, Inner nuclear layer, EN, AMF, CET, Retinal degeneration, Geographic atrophy, Neural engineering, PRIMA, Total, Vance DeGeneres, Moorfields Eye Hospital, Primavera, Retina, Research, Mnemos EP, Optical coherence tomography, Risk, Institute, Nervous system, University, Company, INL, Vision Institute, Rehabilitation, Safety, Journal, IMO, UPMC, Stanford University, AMD, Medical device, Patient

Previously, the data from the French feasibility study already demonstrated that the Prima System is well tolerated.

Key Points: 
  • Previously, the data from the French feasibility study already demonstrated that the Prima System is well tolerated.
  • The data in this paper now further demonstrate the stability and minimal impact of the implant once in position.
  • Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.
  • Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD).

Pixium Vision to host open house event for investors on October 13th 2022 from 5 pm

Retrieved on: 
Wednesday, September 21, 2022
Diamond, Institute, Risk, Retinal degeneration, Safety, UPMC, Company, Mnemos EP, Moorfields Eye Hospital, Primavera, IMO, Patient, Ownership, Technology, Vance DeGeneres, Vision Institute, Prima, EN, CET, Stanford University, Research, AMF, AMD, Virtual reality, Rehabilitation, University, Pharmaceutical industry, Medical device

Paris, France, September 21, 2022 07:00 CET Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today it will host an open house event for investors on Thursday, October 13th, 2022.

Key Points: 
  • Paris, France, September 21, 2022 07:00 CET Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today it will host an open house event for investors on Thursday, October 13th, 2022.
  • There will be a guided visit to the Pixium Vision laboratories including a technology demonstration.
  • The event will conclude with a drinks reception giving an opportunity to talk directly with the Pixium Vision team and use virtual reality to better apprehend the Prima system.
  • Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.

Pixium Vision announces reaching its enrollment target in the European pivotal trial PRIMAvera and implantations planned to be completed by end 2022

Retrieved on: 
Monday, September 19, 2022
Institute, Risk, Retinal degeneration, Safety, Vision, UPMC, Company, Mnemos EP, Moorfields Eye Hospital, Primavera, LogMAR chart, IMO, Patient, Vance DeGeneres, Visual acuity, Vision Institute, Geographic atrophy, EN, CET, Stanford University, Research, AMF, AMD, Rehabilitation, University, Medical device, Pharmaceutical industry

A total of 38 patients have been enrolled in the PRIMAvera study (NCT04676854), an open-label, baseline-controlled, non-randomized, multi-center, prospective single-arm pivotal trial.

Key Points: 
  • A total of 38 patients have been enrolled in the PRIMAvera study (NCT04676854), an open-label, baseline-controlled, non-randomized, multi-center, prospective single-arm pivotal trial.
  • The study was initiated in Q4 2020 in France, where the first patient was enrolled in December 2020.
  • Pixium Vision has since established additional clinical sites and implanted patients in France, Germany, the UK, the Netherlands, and Italy.
  • Implantations are due to be completed by the end of 2022, and a read-out of the PRIMAvera study's primary endpoints is expected around the end of 2023.

Pixium Vision announces implantation of first patient in Italy in Prima System European pivotal trial PRIMAvera

Retrieved on: 
Tuesday, September 13, 2022
Institute, Risk, Retinal degeneration, Safety, UPMC, PRIMA, Hope, Company, Mnemos EP, Moorfields Eye Hospital, Primavera, LogMAR chart, IMO, Patient, Visual acuity, Vance DeGeneres, Vision Institute, EN, CET, Stanford University, Research, AMF, AMD, Rehabilitation, University, Disease, Dentistry, Medical device, Medical imaging, Health

The PRIMAvera study aims to confirm the safety and the benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe.

Key Points: 
  • The PRIMAvera study aims to confirm the safety and the benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe.
  • Pixium Vision has since established additional clinical sites and implanted patients in Germany, the UK and the Netherlands.
  • "We are very pleased to have successfully implanted the first patient in Italy with the Prima System as part of the expanding PRIMAvera pivotal study," said Prof. Andrea Cusumano, co-investigator of the PRIMAvera study for Italy.
  • A total of 38 patients will be implanted in the PRIMAvera study, an open-label, baseline-controlled, non-randomized, multi-center, prospective, single-arm pivotal trial.

Cegid Enters Into a Definitive Agreement to Combine With Grupo Primavera

Retrieved on: 
Tuesday, July 26, 2022
Software, Accounting, Internet, Professional Services, Business, Fintech, Data Management, Payments, Technology, Digital Cash Management, Digital Assets, Human Resources, Consulting, CPAS, Acquisition, Oakley, Grupo Bimbo, Human resources, Treasury, Tax, KKR, SMB, Primavera, CEO, ERP, Solution, Compliance, Partnership, Board, Multimedia, Philosophy, Leadership, Silver, Technology, Ecosystem, Hemne Orkladal Billag, Growth, Video game, Management, Renewable energy, Retail, Camp Ekon, Accounting

View the full release here: https://www.businesswire.com/news/home/20220726005606/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220726005606/en/
    The combination of Cegid and Grupo Primavera underscores Cegids position as a strong provider of cloud-based management solutions.
  • Oakley Capital, which created Grupo Primavera through a series of twelve acquisitions and is its majority shareholder, will join KKR and AltaOne as minority shareholders in Cegid.
  • Together, these shareholders will partner with Cegid CEO Pascal Houillon, Grupo Primavera CEO Santiago Solanas, and the rest of the management team in Cegids next phase of growth.
  • Together, Grupo Primavera and Cegid will have pro forma revenue in the Iberia region of more than 150 million this year.

Pixium Vision announces its financial results for H1 2022 and provides a business update

Retrieved on: 
Friday, July 22, 2022
CIR, Group, Euronext Growth, R, Stanford University, IMO, University, UPMC, Moorfields Eye Hospital, Research, Stanford University School of Medicine, Primavera, Vision Institute, Risk, AMD, EN, Vance DeGeneres, Traction, Marketing, Rehabilitation, Institute, AMF, Safety, Nature Communications, Company, ESGO, Patient, Retinal degeneration, Private law, European, G&A, Medical device, Renewable energy, Pharmaceutical industry

Despite the downturn on the financial markets, Pixium Vision was able to secure the financing as announced July 14, 2022.

Key Points: 
  • Despite the downturn on the financial markets, Pixium Vision was able to secure the financing as announced July 14, 2022.
  • Current general and administrative (G&A) expenses totalled 3.1 million in H1 2022, compared to 2.9 million in H1 2021.
  • Net cash outflow from operating activities increased in H1 2022 to 7.1 million, compared to 6.1 million in H1 2021.
  • Pixium Vision ended H1 2022 with a net cash position of 7.2 million, compared to 10.1 million a year earlier.